New Delhi, July 1 -- Torrent Pharmaceuticals Ltd's acquisition of a controlling stake in JB Chemicals & Pharmaceuticals Ltd, the largest in the Indian pharma sector since 2015, is expected to bring significant cost synergies. It may also help expand its product portfolio across domestic formulations and the fast-growing contract development and manufacturing organisation (CDMO) segment.

JB Pharma's consolidated revenue in FY25 stood at Rs.3,900 crore, which is about one-third of Torrent's topline. While JB's Ebitda margin has improved by 390 basis points (bps) to 26.3% over FY22-25, it is 630 bps lower than Torrent's FY25 margin of 32.6%

The acquisition will complement Torrent's product portfolio in the cardiac and gastro segments.

"To...